Loading...
Loading...
- Remicade Sales Grew From $1,689M To $1,782M, 7.1%
- Xarelto Sales Grew From $246M To $414M, 68.3%
- Stelara Sales Grew From $543M To $370M, 46.8%
- Olysio/Sovriad $796M
- Velcade Sales Fells From $404M To $389M, Decline Of 3.7%
- Prezista Sales Grew From $410M To $446M, 8.8%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in